Jim Tananbaum
Signal active
Founder and CEO
Bio
Dr. Tananbaum is the founding CEO of Foresite Capital Management.
He has led investments in 21 successful healthcare companies, including Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Amerigroup and Jazz Pharmaceuticals.
Previously, Dr. Tananbaum founded and held management positions at GelTex Pharmaceuticals (acquired by Genzyme for $1.6B) and Theravance.
He holds an M.D. from Harvard Medical School and an M.B.A from Harvard Business School, and a B.S. and B.S.E.E. from Yale University.
Dr. Tananbaum has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale School of Engineering.
Location
San Francisco, California, United States, North America
Social
Primary Organization
Foresite Capital
Founded
2011
Investment
158
Lead investment
49
Exits
60
Employees
51-100
Industry
Financial Services, Venture Capital, Finance, Service Industry, Funding Platform
Jobs history
4
XinThera
Board Member
2021 - Current
Element Biosciences
Board Member
Invalid date - Current
Alumis
Board Member
Invalid date - Current
HealthVerity
Board Member
2019 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Jim Tananbaum is the Founder and CEO at Foresite Capital, based in United States, North America. With a background in Financial Services, Jim Tananbaum has a rich history of leadership and innovation. Jim Tananbaum studied MD unknown @ Harvard Medical School. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
Jim Tananbaum has made 1 investments. Their Latest investment was Series E - Peloton Therapeutics on Feb 20, 2019
Number of investment
1
Number of exits
1
Personal investment
1
| Annouced Date | Organization Name | Funding Round | Money Raised |
|---|---|---|---|
| Feb 20, 2019 | Peloton Therapeutics | Series E - Peloton Therapeutics | 150.0M |
Peloton TherapeuticsPartner investment
27
| Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
|---|---|---|---|---|
| Jan 08, 2024 | Genomics | Series C - Genomics | Foresite Capital | 44.6M |
| Mar 06, 2024 | Alumis | Series C - Alumis | Foresite Capital | 259.0M |
| Jul 11, 2024 | Element Biosciences | Series D - Element Biosciences | Foresite Capital | 277.0M |
| Jul 30, 2024 | Foresight Diagnostics | Series B - Foresight Diagnostics | Foresite Capital | 33.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.